Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VRK1 | Q99986 | 15/20 | 0.77 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.77 |
| ▸ | VRK2 | Q86Y07 | 2/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | BRD4 | O60885 | 1/20 | 0.77 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.77 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.77 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.77 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17780349 | 0.89 | VRK1 (0.68) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL13881333 | 0.87 | VRK1 (1.00) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL30013787 | 0.87 | VRK1 (1.00) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17780574 | 0.85 | RPS6KA3 (0.64) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17780594 | 0.84 | RPS6KA3 (0.56) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL14941101 | 0.83 | RPS6KA3 (0.61) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17780459 | 0.82 | RPS6KA3 (0.54) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17780318 | 0.82 | RPS6KA3 (0.58) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17780457 | 0.82 | RPS6KA3 (0.60) | VRK1RPS6KA3VRK2JAK2BRD4 | |
| SCHEMBL17780395 | 0.81 | RPS6KA3 (0.55) | VRK1RPS6KA3VRK2JAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351974-B2 | Substituted pteridinones for the treatment of cancer | OSI Pharmaceuticals, LLC (US) | 2016-05-31 | — | — | US | claimed |